Holen Sie sich die Stockscreener-App
45.98
3.19%
-1.455
Schlusskurs vom Vortag:
$47.43
Offen:
$47.18
24-Stunden-Volumen:
1.08M
Relative Volume:
0.95
Marktkapitalisierung:
$4.68B
Einnahmen:
$47.30M
Nettoeinkommen (Verlust:
$-225.97M
KGV:
-19.56
EPS:
-2.35
Netto-Cashflow:
$-188.86M
1W Leistung:
+2.40%
1M Leistung:
+3.30%
6M Leistung:
+46.19%
1J Leistung:
+27.06%
1-Tages-Spanne:
$45.23
$48.15
1-Wochen-Bereich:
$42.07
$48.19
52-Wochen-Spanne:
$22.71
$49.82
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Firmenname
Scholar Rock Holding Corp
Sektor
Branche
Telefon
857-259-3860
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
45.88 | 4.84B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.38 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.30 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.15 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.85 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Citigroup | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-10-09 | Eingeleitet | BofA Securities | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Fortgesetzt | Jefferies | Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-26 | Bestätigt | H.C. Wainwright | Buy |
| 2024-10-07 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-28 | Eingeleitet | Raymond James | Strong Buy |
| 2023-10-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-07-12 | Eingeleitet | Truist | Buy |
| 2022-03-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-12 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Scholar Rock Holding Corp Aktie (SRRK) Neueste Nachrichten
FY2030 EPS Estimates for Scholar Rock Raised by Analyst - MarketBeat
Scholar Rock (SRRK) Q4 2025 Earnings Transcript - AOL.com
Fisher Asset Management LLC Has $19.86 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock at TD Cowen Conference: Strategic Vision and Challenges - Investing.com Nigeria
Piper Sandler raises Scholar Rock stock price target on SMA launch - Investing.com India
SRRK: Citigroup Raises Price Target to $58, Maintains Buy Rating | SRRK Stock News - GuruFocus
Citigroup Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price - MarketBeat
Scholar Rock Holding (SRRK) Sees Price Target Raised by Truist S - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Piper Sandler Raises Price Target for SRRK to $58.00, Maintains Overweight Rating | SRRK Stock News - GuruFocus
Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume Following Earnings Beat - MarketBeat
Barclays Raises Price Target for Scholar Rock Holding (SRRK) to $53 | SRRK Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating - marketscreener.com
Aisling Capital Management LP Takes $2.87 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Decoding Scholar Rock Holding Corp (SRRK): A Strategic SWOT Insi - GuruFocus
SRRK Technical Analysis & ETF Price Forecast - Intellectia AI
Raymond James Maintains Strong Buy on Scholar Rock (SRRK) Mar 2026 - Meyka
Scholar Rock (NASDAQ: SRRK) posts 2025 loss, expands debt capacity - Stock Titan
Barclays raises Scholar Rock stock price target to $53 on debt deal - Investing.com
Scholar Rock (SRRK) Revises Financial Results for Q4 2025 - GuruFocus
Truist raises Scholar Rock stock price target on manufacturing progress By Investing.com - Investing.com Australia
Truist raises Scholar Rock stock price target on manufacturing progress - Investing.com
Raymond James reiterates Scholar Rock stock Strong Buy on debt facility - Investing.com India
Scholar Rock Q4 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Gap UpTime to Buy? - MarketBeat
Scholar Rock Q4 2025 Earnings Call Transcript - MarketBeat
Scholar Rock Holding (SRRK) Receives Reiterated 'Buy' Rating fro - GuruFocus
Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright - MarketBeat
Scholar Rock Holding Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Scholar Rock Q4 2025 shows slight EPS beat, stock rises - Investing.com
Scholar Rock Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Scholar Rock (SRRK) Poised for FDA Resubmission of Apitegromab - GuruFocus
Vanguard Group Inc. Has $183.03 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (NASDAQ:SRRK) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 - ChartMill
Scholar Rock FY income from operations USD -384.645 million - marketscreener.com
Scholar Rock Advances Apitegromab Toward SMA Commercial Launch - TipRanks
Scholar Rock (SRRK) 2025 loss widens as SMA programs advance - Stock Titan
Scholar Rock Holding 10-K: Operating loss $384.6M, Net loss $377.9M - TradingView
Scholar Rock Q4 Net Loss Widens - marketscreener.com
SRRKForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Earnings Flash (SRRK) Scholar Rock Posts Q4 Net Loss $0.88 a Share, vs. FactSet Est of $0.89 Loss - marketscreener.com
Apitegromab and SRK-439 lead Scholar Rock (NASDAQ: SRRK) neuromuscular pipeline - Stock Titan
Scholar Rock Holding: Q4 Earnings Insights - Benzinga
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Stock Titan
Scholar Rock Holding Corporation $SRRK Shares Purchased by Rafferty Asset Management LLC - MarketBeat
SRRK Earnings History & Surprises | EPS & Revenue Results | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Finanzdaten der Scholar Rock Holding Corp-Aktie (SRRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.07%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):